Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Retinoid X receptors (RXRs) and peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in fatty acid sensing with therapeutic potential in neurodegeneration.
• The compound Wy14,643 exhibits pleiotropic activities in neurodegeneration models beyond its known PPAR agonism.

Purpose of the Study:

• To characterize Wy14,643 as an RXR agonist, elucidating its pleiotropic effects.
• To conduct a structure-activity relationship analysis to identify molecular determinants for PPAR and RXR activity.
• To design novel selective and dual RXR/PPAR agonists as pharmacological tools.

Main Methods:

• Chemical synthesis of Wy14,643 analogues.
• Structure-activity relationship analysis.
• In vitro and in vivo testing of novel compounds.
• Assessment of RXR/liver X receptor (LXR)-mediated side effects.

Main Results:

• Wy14,643 was identified as an RXR agonist, explaining its broad effects.
• Specific molecular determinants for PPAR and RXR activity were discovered.
• Optimized RXR agonists demonstrated in vivo activity in the brain at relevant concentrations.
• A novel RXR agonist exhibited no RXR/LXR-mediated side effects, outperforming classical rexinoids.

Conclusions:

• Wy14,643 possesses dual PPAR and RXR agonistic properties, contributing to its therapeutic potential in neurodegeneration.
• Novel RXR modulators with improved safety and efficacy profiles have been developed.
• These findings establish a new class of RXR modulators for overcoming challenges in RXR-targeted drug discovery for neurological disorders.